Pharmacogenomics : An evolving clinical tool for precision medicine
Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved..
Pharmacogenomics, ie, the study of how an individual's genomic profile influences his or her response to drugs, has emerged as a clinical tool to optimize drug therapy. Certain variants in some genes increase the risk of severe, life-threatening adverse effects from certain drugs. Integrating pharmacogenomics into clinical practice to assist in drug selection and dosing has the potential to improve the outcomes of treatment, reduce the risk of drug-induced morbidity and death, and be cost-effective.
Errataetall: |
CommentIn: Cleve Clin J Med. 2020 Feb;87(2):71-72. - PMID 32015054 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
---|---|
Enthalten in: |
Cleveland Clinic journal of medicine - 87(2020), 2 vom: 03. Feb., Seite 91-99 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hockings, Jennifer K [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 16.11.2020 Date Revised 07.12.2022 published: Print CommentIn: Cleve Clin J Med. 2020 Feb;87(2):71-72. - PMID 32015054 Citation Status MEDLINE |
---|
doi: |
10.3949/ccjm.87a.19073 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM306105780 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM306105780 | ||
003 | DE-627 | ||
005 | 20231225122632.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3949/ccjm.87a.19073 |2 doi | |
028 | 5 | 2 | |a pubmed24n1020.xml |
035 | |a (DE-627)NLM306105780 | ||
035 | |a (NLM)32015062 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hockings, Jennifer K |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pharmacogenomics |b An evolving clinical tool for precision medicine |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 16.11.2020 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print | ||
500 | |a CommentIn: Cleve Clin J Med. 2020 Feb;87(2):71-72. - PMID 32015054 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved. | ||
520 | |a Pharmacogenomics, ie, the study of how an individual's genomic profile influences his or her response to drugs, has emerged as a clinical tool to optimize drug therapy. Certain variants in some genes increase the risk of severe, life-threatening adverse effects from certain drugs. Integrating pharmacogenomics into clinical practice to assist in drug selection and dosing has the potential to improve the outcomes of treatment, reduce the risk of drug-induced morbidity and death, and be cost-effective | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a Antidepressive Agents, Tricyclic |2 NLM | |
650 | 7 | |a Serotonin Uptake Inhibitors |2 NLM | |
650 | 7 | |a Clopidogrel |2 NLM | |
650 | 7 | |a A74586SNO7 |2 NLM | |
650 | 7 | |a CYP2C19 protein, human |2 NLM | |
650 | 7 | |a EC 1.14.14.1 |2 NLM | |
650 | 7 | |a Cytochrome P-450 CYP2C19 |2 NLM | |
650 | 7 | |a EC 1.14.14.1 |2 NLM | |
650 | 7 | |a Cytochrome P-450 CYP2D6 |2 NLM | |
650 | 7 | |a EC 1.14.14.1 |2 NLM | |
650 | 7 | |a Codeine |2 NLM | |
650 | 7 | |a UX6OWY2V7J |2 NLM | |
700 | 1 | |a Pasternak, Amy L |e verfasserin |4 aut | |
700 | 1 | |a Erwin, Angelika L |e verfasserin |4 aut | |
700 | 1 | |a Mason, Neil T |e verfasserin |4 aut | |
700 | 1 | |a Eng, Charis |e verfasserin |4 aut | |
700 | 1 | |a Hicks, J Kevin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cleveland Clinic journal of medicine |d 1996 |g 87(2020), 2 vom: 03. Feb., Seite 91-99 |w (DE-627)NLM012620769 |x 1939-2869 |7 nnns |
773 | 1 | 8 | |g volume:87 |g year:2020 |g number:2 |g day:03 |g month:02 |g pages:91-99 |
856 | 4 | 0 | |u http://dx.doi.org/10.3949/ccjm.87a.19073 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 87 |j 2020 |e 2 |b 03 |c 02 |h 91-99 |